Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma

J Nucl Med. 2005 May;46(5):770-4.

Abstract

The aim of this retrospective study was to evaluate the sensitivity and prognostic significance of whole-body (18)F-FDG PET for nasopharyngeal carcinoma (NPC) patients for whom there was a suspicion of recurrence or metastasis by conventional radiologic or clinical findings during their follow-up examinations.

Methods: Whole-body (18)F-FDG PET examinations were performed on 64 Taiwanese NPC patients (14 female, 50 male; mean age +/- SD, 45.8 +/- 13.0 y; age range, 16-75 y) 4-70 mo (mean +/- SD, 14.1 +/- 13.5 mo) after radiotherapy or induction chemotherapy followed by concurrent chemoradiotherapy from February 1997 to May 2001. The accuracy of (18)F-FDG PET detection for each patient was determined by the histopathologic results or other clinical evidence.

Results: The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of (18)F-FDG PET images in the diagnosis of NPC recurrence or metastases and secondary primary cancers were 92%, 90%, 92%, 90%, and 91%, respectively. Furthermore, the presence of (18)F-FDG hypermetabolism was highly correlated with the survival time of NPC patients.

Conclusion: Whole-body (18)F-FDG PET is a sensitive follow-up diagnostic tool for the evaluation of NPC recurrences and metastases. It is also an effective prognostic indicator for NPC patients. To determine the optimized utilization of (18)F-FDG PET in the follow-up for NPC patients, further cost-effectiveness analysis of (18)F-FDG PET in combination with conventional management is necessary.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Carcinoma / diagnostic imaging*
  • Carcinoma / secondary*
  • Carcinoma / therapy
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Middle Aged
  • Nasopharyngeal Neoplasms / diagnostic imaging*
  • Nasopharyngeal Neoplasms / therapy
  • Neoplasm Recurrence, Local / diagnostic imaging*
  • Positron-Emission Tomography / methods*
  • Prognosis
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Retrospective Studies
  • Risk Assessment / methods*
  • Risk Factors
  • Sensitivity and Specificity
  • Treatment Outcome
  • Whole-Body Counting / methods

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18